I-MAB (IMAB) Price & Analysis

Compare

397 Followers

IMAB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.60 - $5.90

Previous CloseN/A

Volume876.01K

Average Volume (3M)2.26M

Market Cap

$292.22M

Enterprise Value$35.58M

Total Cash (Recent Filing)$184.39M

Total Debt (Recent Filing)$3.78M

Price to Earnings (P/E)―

Beta1.80

Next Earnings

Nov 13, 2025

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding81,660,350

10 Day Avg. Volume1,763,587

30 Day Avg. Volume2,259,551

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.12

Enterprise Value/Revenue8.91

Enterprise Value/Gross Profit8.91

Enterprise Value/Ebitda-0.12

Forecast

1Y Price Target

$7.00

Price Target Upside89.70% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsClinical trials for Givastomig are fully U.S. based, minimizing regulatory concerns related to Chinese data.

Financial StabilityThe August 2025 financing extends cash runway into the fourth quarter of 2028, allowing I-Mab to carry givastomig through a randomized Phase 2 trial.

Market ExpansionGivastomig's 10x more potent conditional 4-1BB design drives activity across CLDN18.2-low and PD-L1-low populations, effectively doubling the addressable market.

Bears Say

Stock Price VolatilityI-Mab shares fell ~20% following a New York Times article, which is seen as an unwarranted mispricing due to the mischaracterization of I-Mab as a Chinese drugmaker.

I-MAB News

Trump Trade: Offshore wind seen with no future in the U.S. under Trump

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

9d ago

BEP

BTIG says buy I-Mab amid ‘misperceived’ China risk

BTIG analyst Justin Zelin notes that I-Mab (IMAB) shares have fallen about 20% following a New York Times...

9d ago

IMAB

I-Mab initiated with a Buy at BTIG

BTIG initiated coverage of I-Mab (IMAB) with a Buy rating and $7 price target The firm believes givastomig...

11d ago

IMAB

I-Mab announces accelerated investment in givastomig program

I-Mab (IMAB) announced accelerated investment in its lead program, givastomig, an investigational Claudin 18.2-directed bispecific antibody, including plans...

12d ago

IMAB

I-Mab appoints Lenz, Liu to board of directors, forms R&D Committee

I-Mab (IMAB) announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board...

26d ago

IMAB

I-Mab’s Strategic Expansion and Financial Stability Justify Buy Rating Amid Promising Clinical Developments

Needham analyst Gil Blum maintained a Buy rating on I-MAB today and set a price target of $6.00....

12d ago

IMAB

I-Mab Announces Leadership Changes and Accelerated Investment in Givastomig

An announcement from I-MAB ( ($IMAB) ) is now available. On September 3, 2025, I-Mab announced significant leadership...

12d ago

IMAB

I-Mab Strengthens Leadership with New Board Appointments and R&D Committee Formation

I-MAB ( ($IMAB) ) has provided an update. On August 22, 2025, I-Mab announced the appointment of Dr....

26d ago

IMAB

I-Mab’s Q2 2025: Clinical Progress and Financial Strength

I-Mab Adr ( ($IMAB) ) has released its Q2 earnings. Here is a breakdown of the information I-Mab...

30d ago

IMAB

I-Mab price target raised to $6 from $5 at Needham

Needham raised the firm’s price target on I-Mab (IMAB) to $6 from $5 and keeps a Buy rating...

1M ago

IMAB

I-MAB’s Positive Outlook: Buy Rating Backed by Financial Stability and Promising Clinical Developments

Analyst Gil Blum of Needham maintained a Buy rating on I-MAB, boosting the price target to $6.00. Gil...

1M ago

IMAB

I-Mab Reports Strong Financials and Clinical Progress in August 2025

I-MAB ( ($IMAB) ) just unveiled an update. On August 20, 2025, I-Mab announced its financial results for...

1M ago

IMAB

I-Mab reports Q2 EPS (3c), consensus (5c)

“The first half of 2025 has been transformative for I-Mab (IMAB),” said Sean Fu, PhD, Chief Executive Officer...

1M ago

IMAB

I-Mab sees cash runway through 4Q28

As of June 30, 2025, the Company had cash and cash equivalents, and short-term investments of $165.6 million....

1M ago

IMAB

IMAB FAQ

What was I-MAB’s price range in the past 12 months?

I-MAB lowest stock price was $0.59 and its highest was $5.90 in the past 12 months.

What is I-MAB’s market cap?

I-MAB’s market cap is $292.22M.

When is I-MAB’s upcoming earnings report date?

I-MAB’s upcoming earnings report date is Nov 13, 2025 which is in 54 days.

How were I-MAB’s earnings last quarter?

I-MAB released its earnings results on Aug 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.024.

Is I-MAB overvalued?

According to Wall Street analysts I-MAB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does I-MAB pay dividends?

I-MAB does not currently pay dividends.

What is I-MAB’s EPS estimate?

I-MAB’s EPS estimate is -0.04.

How many shares outstanding does I-MAB have?

I-MAB has 81,660,350 shares outstanding.

What happened to I-MAB’s price movement after its last earnings report?

I-MAB reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 7.363%.

Which hedge fund is a major shareholder of I-MAB?

Currently, no hedge funds are holding shares in IMAB

I-MAB Stock Smart Score

Outperform

Fundamentals

Return on Equity

-22.37%

Trailing 12-Months

Asset Growth

-42.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

I-MAB

I-MAB (IMAB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The company is engaged in the development of innovative monoclonal antibodies and biologics, leveraging its integrated research and development capabilities. I-MAB aims to address unmet medical needs through its proprietary drug discovery and development platforms.

I-MAB (IMAB) Earnings & Revenues

Historic Earnings Reports

IMAB Stock 12 Month Forecast

Average Price Target

$7.00

▲(89.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.37,4.649230769230769,4.928461538461539,5.207692307692308,5.486923076923077,5.766153846153847,6.045384615384616,6.3246153846153845,6.603846153846154,6.883076923076923,7.162307692307692,7.441538461538462,7.720769230769231,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.37,4.572307692307692,4.774615384615385,4.976923076923077,5.179230769230769,5.381538461538462,5.583846153846154,5.786153846153846,5.9884615384615385,6.190769230769231,6.393076923076923,6.595384615384615,6.797692307692308,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.37,4.495384615384616,4.6207692307692305,4.746153846153846,4.871538461538462,4.996923076923077,5.122307692307692,5.247692307692308,5.373076923076923,5.498461538461538,5.623846153846154,5.749230769230769,5.874615384615384,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.79,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >